Two of the most anxiety-inducing questions circulating among parents and clinicians — whether a common pain reliever taken during pregnancy raises autism risk, and whether a B-vitamin derivative can meaningfully improve autistic children's communication — now have considerably clearer, if still imperfect, answers. The implications cut across prenatal care decisions and post-diagnosis supplement use alike.
A review published in the Journal of Autism and Developmental Disorders synthesizes the strongest available evidence on both questions. On acetaminophen, the most methodologically rigorous data comes from a Swedish population cohort of nearly 2.5 million individuals. By applying a sibling-control design — which neutralizes shared genetic and environmental confounders that plague standard observational studies — researchers found no meaningful association between prenatal acetaminophen exposure and autism, ADHD, or intellectual disability. This design is particularly powerful because earlier positive associations in simpler cohorts may have reflected familial factors rather than the drug itself. On folinic acid (leucovorin), several small randomized trials have reported short-term gains in verbal and social communication, with signals appearing stronger in children who test positive for folate receptor autoantibodies (FRAA). However, a 2024 trial in this space was retracted in January 2026 — an unusually significant event that underscores how fragile early findings in this literature remain.
From a broader research perspective, the acetaminophen finding is reassuring precisely because sibling-controlled designs represent the gold standard for disentangling drug effects from heritable confounding in observational research. The folinic acid story is more cautionary: FRAA-positive subgroups are biologically plausible targets, but small single-center trials with variable outcome measures are notoriously prone to false-positive results, and the recent retraction demands that clinicians withhold strong clinical recommendations pending larger, multi-site replication. Taken together, this review exemplifies why mechanistically plausible hypotheses require rigorous methodological scrutiny before influencing clinical practice or parental decision-making.